Previous studies have demonstrated that ENO1 overexpression was positively associated with progression and poor prognosis in neuroendocrine tumors, neuroblastoma, pancreatic cancer, prostate cancer, cholangiocarcinoma, thyroid carcinoma, hepatocellular carcinoma, and breast cancer [14,21-27]. This evidence concerns the gene ENO1 and prostate carcinoma.